Guggenheim lowered the firm’s price target on BeiGene to $345 from $350 and keeps a Buy rating on the shares after the company reported Q4 results and said early pipeline developments remain on track. BeiGene reaffirmed plans to initiate Phase 1 trials for 10 new molecules in 2024, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
